Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in HER2-negative Breast Cancer.

Rousseau C, Goldenberg DM, Colombie M, Sebille JC, Meingan P, Ferrer L, Baumgartner P, Cerato E, Masson D, Campone M, Rauscher A, Fleury V, Labbe C, Faivre-Chauvet A, Frenel JS, Toquet C, Barbet J, Sharkey RM, Campion L, Kraeber-Bodere F.

J Nucl Med. 2020 Mar 13. pii: jnumed.119.236000. doi: 10.2967/jnumed.119.236000. [Epub ahead of print]

PMID:
32169921
2.

Medical oncologists must get more involved in systemic treatment.

Raoul JL, Faivre S, Frenel JS, Rimassa L.

Ann Oncol. 2019 Jan;30(1):6-8. doi: 10.1093/annonc/mdy471. Epub 2020 Jan 8. No abstract available.

PMID:
32081277
3.

[Proton pump inhibitors and cancers: A hazardous association?]

Raoul JL, Edeline J, Gilabert M, Senellart H, Frenel JS.

Bull Cancer. 2020 Feb 10. pii: S0007-4551(20)30060-6. doi: 10.1016/j.bulcan.2019.12.009. [Epub ahead of print] Review. French.

PMID:
32057465
4.

Cell-free circulating epimarks in cancer monitoring.

Duforestel M, Briand J, Bougras-Cartron G, Heymann D, Frenel JS, Vallette FM, Cartron PF.

Epigenomics. 2020 Jan;12(2):145-155. doi: 10.2217/epi-2019-0170. Epub 2020 Jan 9.

PMID:
31916450
5.

[Retrospective study: Late surgery post chemotherapy versus after 3-4 cures in treatment of advanced ovarian cancer].

de Fréminville Q, Licaj I, Frenel JS, Hamel-Senecal L, Thomas G, Brachet PE, Coquan E, Leconte A, Classe JM, Joly F.

Bull Cancer. 2020 Feb;107(2):157-170. doi: 10.1016/j.bulcan.2019.10.004. Epub 2019 Dec 16. French.

PMID:
31858981
6.

Paracaspase MALT1 regulates glioma cell survival by controlling endo-lysosome homeostasis.

Jacobs KA, André-Grégoire G, Maghe C, Thys A, Li Y, Harford-Wright E, Trillet K, Douanne T, Alves Nicolau C, Frénel JS, Bidère N, Gavard J.

EMBO J. 2020 Jan 2;39(1):e102030. doi: 10.15252/embj.2019102030. Epub 2019 Nov 27.

PMID:
31774199
7.

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFRamplified glioblastoma.

van den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, de Vos F, Whenham N, Sanghera P, Weller M, Dubbink HJ, French P, Looman J, Dey J, Krause S, Ansell P, Nuyens S, Spruyt M, Brilhante J, Coens C, Gorlia T, Golfinopoulos V.

Neuro Oncol. 2019 Nov 20. pii: noz222. doi: 10.1093/neuonc/noz222. [Epub ahead of print]

PMID:
31747009
8.

Glyphosate Primes Mammary Cells for Tumorigenesis by Reprogramming the Epigenome in a TET3-Dependent Manner.

Duforestel M, Nadaradjane A, Bougras-Cartron G, Briand J, Olivier C, Frenel JS, Vallette FM, Lelièvre SA, Cartron PF.

Front Genet. 2019 Sep 27;10:885. doi: 10.3389/fgene.2019.00885. eCollection 2019.

9.

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.

Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, Koch H, Goffin F, González-Martin A, Ottevanger PB, Baumann K, Bjørge L, Lesoin A, Burges A, Rosenberg P, Gropp-Meier M, Harrela M, Harter P, Frenel JS, Minarik T, Pisano C, Hasenburg A, Merger M, du Bois A; AGO Study Group-led GCIG/ENGOT Intergroup Consortium.

Int J Cancer. 2020 Jan 15;146(2):439-448. doi: 10.1002/ijc.32606. Epub 2019 Sep 6.

PMID:
31381147
10.

Current options and future possibilities for the systemic treatment of hepatocellular carcinoma.

Raoul JL, Frenel JS, Raimbourg J, Gilabert M.

Hepat Oncol. 2019 Jun 4;6(1):HEP11. doi: 10.2217/hep-2019-0001. Review.

11.

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data.

du Rusquec P, de Calbiac O, Robert M, Campone M, Frenel JS.

Cancer Manag Res. 2019 May 15;11:4297-4312. doi: 10.2147/CMAR.S151023. eCollection 2019. Review.

12.

Benefits versus risk profile of buparlisib for the treatment of breast cancer.

Patsouris A, Augereau P, Frenel JS, Robert M, Gourmelon C, Bourbouloux E, Berton-Rigaud D, Chevalier LM, Campone M.

Expert Opin Drug Saf. 2019 Jul;18(7):553-562. doi: 10.1080/14740338.2019.1623877. Review.

PMID:
31159599
13.

Defining EGFR amplification status for clinical trial inclusion.

French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Weller M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, van den Bent M.

Neuro Oncol. 2019 Oct 9;21(10):1263-1272. doi: 10.1093/neuonc/noz096.

14.

Pertuzumab for the treatment of breast cancer.

Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M.

Expert Rev Anticancer Ther. 2020 Feb;20(2):85-95. doi: 10.1080/14737140.2019.1596805. Epub 2019 Aug 29.

PMID:
30884986
15.

Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer.

Caruana E, Foucher Y, Tessier P, Frenel JS, Classe JM, Dantan E.

Breast Cancer Res Treat. 2019 Apr;174(2):537-542. doi: 10.1007/s10549-018-05107-6. Epub 2019 Jan 2.

PMID:
30603997
16.

Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.

Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M.

Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):85-91. doi: 10.1080/17425255.2019.1559816. Epub 2019 Jan 5. Review.

PMID:
30577708
17.

miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker.

Nadaradjane A, Briand J, Bougras-Cartron G, Disdero V, Vallette FM, Frenel JS, Cartron PF.

Mol Ther Nucleic Acids. 2018 Dec 7;13:642-650. doi: 10.1016/j.omtn.2018.09.007. Epub 2018 Sep 13.

18.

Medical oncologists must get more involved in systemic treatment of hepatocellular carcinoma.

Raoul JL, Faivre S, Frenel JS, Rimassa L.

Ann Oncol. 2019 Jan 1;30(1):6-8. doi: 10.1093/annonc/mdy471. No abstract available.

19.

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.

Cottu P, D'Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel PE, Duhoux FP, Levy C, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat-Bouvet L, Nguyen S, Ferrero JM, Canon JL, Grenier J, Callens C, Gentien D, Lemonnier J, Vincent-Salomon A, Delaloge S.

Ann Oncol. 2018 Dec 1;29(12):2334-2340. doi: 10.1093/annonc/mdy448.

20.

The self-reported perceptions of the repercussions of the disease and its treatments on daily life for young women with breast cancer and their partners.

Congard A, Christophe V, Duprez C, Baudry AS, Antoine P, Lesur A, Loustalot C, Guillemet C, Leclercq M, Segura C, Carlier D, Lefeuvre-Plesse C, Simon H, Frenel JS, Vanlemmens L.

J Psychosoc Oncol. 2019 Jan-Feb;37(1):50-68. doi: 10.1080/07347332.2018.1479326. Epub 2018 Oct 8.

PMID:
30295567
21.

Emerging PARP inhibitors for treating breast cancer.

Robert M, Patsouris A, Frenel JS, Gourmelon C, Augereau P, Campone M.

Expert Opin Emerg Drugs. 2018 Sep;23(3):211-221. doi: 10.1080/14728214.2018.1527900. Epub 2018 Sep 29. Review.

PMID:
30251552
22.

An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.

Robert M, Frenel JS, Bourbouloux E, Rigaud DB, Patsouris A, Augereau P, Gourmelon C, Campone M.

Drugs. 2018 Sep;78(13):1353-1362. doi: 10.1007/s40265-018-0972-9. Review.

PMID:
30143968
23.

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.

Ploquin A, Pistilli B, Tresch E, Frenel JS, Lerebours F, Lesur A, Loustalot C, Bachelot T, Provansal M, Ferrero JM, Coussy F, Debled M, Kerbrat P, Vinceneux A, Allouache D, Morvan F, Dalenc F, Guiu S, Rouzier R, Vanlemmens L.

Eur J Cancer. 2018 May;95:30-37. doi: 10.1016/j.ejca.2018.02.030. Epub 2018 Apr 3.

PMID:
29625257
24.

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A.

ESMO Open. 2018 Feb 2;3(2):e000285. doi: 10.1136/esmoopen-2017-000285. eCollection 2018.

25.

Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.

du Rusquec P, Palpacuer C, Campion L, Patsouris A, Augereau P, Gourmelon C, Robert M, Dumas L, Caroline F, Campone M, Frenel JS.

Breast Cancer Res Treat. 2018 Apr;168(2):559-566. doi: 10.1007/s10549-017-4623-8. Epub 2017 Dec 15.

PMID:
29247442
26.

Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses.

Duprez C, Vanlemmens L, Untas A, Antoine P, Lesur A, Loustalot C, Guillemet C, Leclercq M, Segura C, Carlier D, Lefeuvre-Plesse C, Simon H, Frenel JS, Christophe V.

Future Oncol. 2017 Dec;13(29):2667-2680. doi: 10.2217/fon-2017-0264. Epub 2017 Dec 1.

PMID:
29191056
27.

Efficacy of buparlisib in treating breast cancer.

Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M.

Expert Opin Pharmacother. 2017 Dec;18(18):2007-2016. doi: 10.1080/14656566.2017.1410139. Epub 2017 Dec 1.

PMID:
29169282
28.

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A.

J Clin Oncol. 2017 Dec 20;35(36):4035-4041. doi: 10.1200/JCO.2017.74.5471. Epub 2017 Nov 2.

PMID:
29095678
29.

Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.

Augereau P, Patsouris A, Bourbouloux E, Gourmelon C, Abadie Lacourtoisie S, Berton Rigaud D, Soulié P, Frenel JS, Campone M.

Ther Adv Med Oncol. 2017 May;9(5):335-346. doi: 10.1177/1758834017693195. Epub 2017 Mar 14. Review.

30.

Olaparib for the treatment of breast cancer.

Robert M, Frenel JS, Gourmelon C, Patsouris A, Augereau P, Campone M.

Expert Opin Investig Drugs. 2017 Jun;26(6):751-759. doi: 10.1080/13543784.2017.1318847. Epub 2017 Apr 21. Review.

PMID:
28395540
31.

Vinflunine for the treatment of breast cancer.

Gourmelon C, Bourien H, Augereau P, Patsouris A, Frenel JS, Campone M.

Expert Opin Pharmacother. 2016 Sep;17(13):1817-23. doi: 10.1080/14656566.2016.1217991. Epub 2016 Aug 10. Review.

PMID:
27484180
32.

Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study.

Cabart M, Frénel JS, Campion L, Ramée JF, Dupuis O, Senellart H, Hiret S, Douillard JY, Bennouna J.

Clin Colorectal Cancer. 2016 Dec;15(4):e165-e174. doi: 10.1016/j.clcc.2016.04.009. Epub 2016 May 7.

PMID:
27256668
33.

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

Jacot W, Pons E, Frenel JS, Guiu S, Levy C, Heudel PE, Bachelot T, D'Hondt V, Darlix A, Firmin N, Romieu G, Thezenas S, Dalenc F.

Breast Cancer Res Treat. 2016 Jun;157(2):307-318. doi: 10.1007/s10549-016-3828-6. Epub 2016 May 11.

PMID:
27167986
34.

[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].

Cabart M, Frénel JS, Campion L, Ramée JF, Dupuis O, Senellart H, Hiret S, Douillard JY, Bennouna J.

Bull Cancer. 2016 Jun;103(6):541-51. doi: 10.1016/j.bulcan.2016.03.007. Epub 2016 May 5. French.

PMID:
27155924
35.

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M, Stupp R, Roth P, Golfinopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Hegi ME.

Clin Cancer Res. 2016 Oct 1;22(19):4797-4806. Epub 2016 May 3.

36.

[Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].

Frenel JS, Bally O, Bourbouloux E, Berton-Rigaud D, Campone M, Bachelot T, Heudel PÉ.

Bull Cancer. 2016 May;103(5):507-10. doi: 10.1016/j.bulcan.2016.02.005. Epub 2016 Mar 15. Review. French. No abstract available.

PMID:
26992855
37.

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.

Awada A, Campone M, Varga A, Aftimos P, Frenel JS, Bahleda R, Gombos A, Bourbouloux E, Soria JC.

Anticancer Drugs. 2016 Apr;27(4):342-8. doi: 10.1097/CAD.0000000000000336.

PMID:
26796987
38.

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas.

Alentorn A, Dehais C, Ducray F, Carpentier C, Mokhtari K, Figarella-Branger D, Chinot O, Cohen-Moyal E, Ramirez C, Loiseau H, Elouahdani-Hamdi S, Beauchesne P, Langlois O, Desenclos C, Guillamo JS, Dam-Hieu P, Ghiringhelli F, Colin P, Godard J, Parker F, Dhermain F, Carpentier AF, Frenel JS, Menei P, Bauchet L, Faillot T, Fesneau M, Fontaine D, Motuo-Fotso MJ, Vauleon E, Gaultier C, Le Guerinel C, Gueye EM, Noel G, Desse N, Durando X, Barrascout E, Wager M, Ricard D, Carpiuc I, Delattre JY, Idbaih A; POLA Network.

Neurology. 2015 Oct 13;85(15):1325-31. doi: 10.1212/WNL.0000000000002014. Epub 2015 Sep 18.

39.

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.

Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi Tandefelt D, Turner N, Attard G, de Bono JS.

Clin Cancer Res. 2015 Oct 15;21(20):4586-96. doi: 10.1158/1078-0432.CCR-15-0584. Epub 2015 Jun 17.

40.

[Unusual antenatal gestational choriocarcinoma].

Tardif C, Nowak C, Sagan C, Frenel JS, Philippe HJ.

Gynecol Obstet Fertil. 2014 Oct;42(10):725-8. doi: 10.1016/j.gyobfe.2014.07.033. Epub 2014 Sep 18. French.

PMID:
25242439
41.

Tumor clone dynamics in lethal prostate cancer.

Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel JS, Pezaro C, Omlin A, Rodrigues DN, Flohr P, Tunariu N, S de Bono J, Demichelis F, Attard G.

Sci Transl Med. 2014 Sep 17;6(254):254ra125. doi: 10.1126/scitranslmed.3009448.

42.

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.

Frenel JS, Leux C, Loussouarn D, Le Loupp AG, Leclair F, Aumont M, Mervoyer A, Martin S, Denis MG, Campone M.

J Neurooncol. 2013 Aug;114(1):85-91. doi: 10.1007/s11060-013-1152-0. Epub 2013 May 17.

PMID:
23681562
43.

bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses.

Jézéquel P, Frénel JS, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G, Campone M.

Database (Oxford). 2013 Jan 15;2013:bas060. doi: 10.1093/database/bas060. Print 2013.

44.

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series.

Rodrigues MJ, Peron J, Frénel JS, Vano YA, Wassermann J, Debled M, Picaud F, Albiges L, Vincent-Salomon A, Cottu PH.

Ann Oncol. 2013 Apr;24(4):916-24. doi: 10.1093/annonc/mds536. Epub 2012 Oct 26.

45.

Pulse oximetry and high-dose vasopressors: a comparison between forehead reflectance and finger transmission sensors.

Nesseler N, Frénel JV, Launey Y, Morcet J, Mallédant Y, Seguin P.

Intensive Care Med. 2012 Oct;38(10):1718-22. Epub 2012 Aug 7.

PMID:
22868275
46.

[Tumor resistance to HER2 inhibitors: the drug sedimentation concept].

Campone M, Frenel JS, André F, Bachelot T, Juin P.

Bull Cancer. 2012 Jun;99(6):665-72. doi: 10.1684/bdc.2012.1591. Review. French.

47.

Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.

Loussouarn D, Le Loupp AG, Frenel JS, Leclair F, Von Deimling A, Aumont M, Martin S, Campone M, Denis MG.

Int J Oncol. 2012 Jun;40(6):2058-62. doi: 10.3892/ijo.2012.1404. Epub 2012 Mar 16.

PMID:
22447191
48.

What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?

Gourmelon C, Frenel JS, Campone M.

Expert Rev Anticancer Ther. 2012 Feb;12(2):195-201. doi: 10.1586/era.11.167. Review.

PMID:
22316367
49.

Eribulin mesylate for the treatment of late-stage breast cancer.

Gourmelon C, Frenel JS, Campone M.

Expert Opin Pharmacother. 2011 Dec;12(18):2883-90. doi: 10.1517/14656566.2011.637490. Epub 2011 Nov 17. Review.

PMID:
22087618
50.

Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases.

Classe JM, Jaffre I, Frenel JS, Bordes V, Dejode M, Dravet F, Ferron G, Marchal F, Rigaud DB, Loussouarn D, Campion L.

Eur J Surg Oncol. 2011 Nov;37(11):971-7. doi: 10.1016/j.ejso.2011.08.138. Epub 2011 Sep 25.

PMID:
21944959

Supplemental Content

Loading ...
Support Center